Cargando…

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kun, Wang, Shuhang, Qi, Dan, Ma, Peiwen, Fang, Yuan, Jiang, Ning, Wu, Erxi, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339623/
https://www.ncbi.nlm.nih.gov/pubmed/35924243
http://dx.doi.org/10.3389/fimmu.2022.896685
_version_ 1784760208100163584
author Chen, Kun
Wang, Shuhang
Qi, Dan
Ma, Peiwen
Fang, Yuan
Jiang, Ning
Wu, Erxi
Li, Ning
author_facet Chen, Kun
Wang, Shuhang
Qi, Dan
Ma, Peiwen
Fang, Yuan
Jiang, Ning
Wu, Erxi
Li, Ning
author_sort Chen, Kun
collection PubMed
description Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing. However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed. Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries.
format Online
Article
Text
id pubmed-9339623
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93396232022-08-02 Clinical Investigations of CAR-T Cell Therapy for Solid Tumors Chen, Kun Wang, Shuhang Qi, Dan Ma, Peiwen Fang, Yuan Jiang, Ning Wu, Erxi Li, Ning Front Immunol Immunology Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing. However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed. Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries. Frontiers Media S.A. 2022-07-18 /pmc/articles/PMC9339623/ /pubmed/35924243 http://dx.doi.org/10.3389/fimmu.2022.896685 Text en Copyright © 2022 Chen, Wang, Qi, Ma, Fang, Jiang, Wu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Kun
Wang, Shuhang
Qi, Dan
Ma, Peiwen
Fang, Yuan
Jiang, Ning
Wu, Erxi
Li, Ning
Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
title Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
title_full Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
title_fullStr Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
title_full_unstemmed Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
title_short Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
title_sort clinical investigations of car-t cell therapy for solid tumors
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339623/
https://www.ncbi.nlm.nih.gov/pubmed/35924243
http://dx.doi.org/10.3389/fimmu.2022.896685
work_keys_str_mv AT chenkun clinicalinvestigationsofcartcelltherapyforsolidtumors
AT wangshuhang clinicalinvestigationsofcartcelltherapyforsolidtumors
AT qidan clinicalinvestigationsofcartcelltherapyforsolidtumors
AT mapeiwen clinicalinvestigationsofcartcelltherapyforsolidtumors
AT fangyuan clinicalinvestigationsofcartcelltherapyforsolidtumors
AT jiangning clinicalinvestigationsofcartcelltherapyforsolidtumors
AT wuerxi clinicalinvestigationsofcartcelltherapyforsolidtumors
AT lining clinicalinvestigationsofcartcelltherapyforsolidtumors